Skip to main content
. Author manuscript; available in PMC: 2024 Oct 15.
Published in final edited form as: Cancer. 2023 Jun 29;129(20):3275–3286. doi: 10.1002/cncr.34927

Figure 5: Cox proportional hazards adjusted survival of patients with hepatic disease at initial diagnosis of metastatic uveal melanoma stratified by use of ICI therapy.

Figure 5:

Separate Cox proportional hazards models adjusting for sex, baseline ECOG (0 vs. ≥ 1), and any receipt of ICI therapy (yes vs. no) were created by cohort (initial and validation). The hazard ratios for ICI use (vs. no use) with 95% confidence intervals are plotted by cohort in panel A. The adjusted cumulative survival curves stratified by receipt of ICI are plotted in panel B.